Summary
We will use a new class of deep ultraviolet light source to address the biggest challenge facing modern medicine: the emergence of antimicrobial resistance (AMR): the resistance of bacteria (so-called “super bugs”) to anti-biotics. AMR is anticipated to cause 10 million deaths annually by 2050. The golden era of antibiotics is over, and the antibiotic pipeline is failing. We need to develop new technologies to target pathogens without antibiotics and to which pathogens cannot develop resistance.
The germicidal properties of ultraviolet light (wavelength around 254 nm) from lamps are well established. Unfortunately, this wavelength is mutagenic to human cells and unsuitable for therapy. However, it has recently been shown that shorter-wavelength deep ultraviolet light (DUVL), such as 207 nm light, maintains germicidal efficacy while limiting mutagenic effects.
While there are existing ways to generate DUVL, they all fail to meet the constraints that must be met for ubiquitous clinical use: compact size, low cost, long lifetime, high robustness and no need for serviceability.
During my ERC Starting Grant project I developed a new route to create high brightness DUVL sources. In this project we will demonstrate the Proof of Concept of a business providing compact, robust, bright and low-cost DUVL sources—based on a down-scaling of my Starting Grant technology—for delivery to confined regions of the body for safe (non-mutagenic to human cells) killing of pathogens.
The germicidal properties of ultraviolet light (wavelength around 254 nm) from lamps are well established. Unfortunately, this wavelength is mutagenic to human cells and unsuitable for therapy. However, it has recently been shown that shorter-wavelength deep ultraviolet light (DUVL), such as 207 nm light, maintains germicidal efficacy while limiting mutagenic effects.
While there are existing ways to generate DUVL, they all fail to meet the constraints that must be met for ubiquitous clinical use: compact size, low cost, long lifetime, high robustness and no need for serviceability.
During my ERC Starting Grant project I developed a new route to create high brightness DUVL sources. In this project we will demonstrate the Proof of Concept of a business providing compact, robust, bright and low-cost DUVL sources—based on a down-scaling of my Starting Grant technology—for delivery to confined regions of the body for safe (non-mutagenic to human cells) killing of pathogens.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/899900 |
| Start date: | 01-03-2020 |
| End date: | 31-08-2021 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
We will use a new class of deep ultraviolet light source to address the biggest challenge facing modern medicine: the emergence of antimicrobial resistance (AMR): the resistance of bacteria (so-called “super bugs”) to anti-biotics. AMR is anticipated to cause 10 million deaths annually by 2050. The golden era of antibiotics is over, and the antibiotic pipeline is failing. We need to develop new technologies to target pathogens without antibiotics and to which pathogens cannot develop resistance.The germicidal properties of ultraviolet light (wavelength around 254 nm) from lamps are well established. Unfortunately, this wavelength is mutagenic to human cells and unsuitable for therapy. However, it has recently been shown that shorter-wavelength deep ultraviolet light (DUVL), such as 207 nm light, maintains germicidal efficacy while limiting mutagenic effects.
While there are existing ways to generate DUVL, they all fail to meet the constraints that must be met for ubiquitous clinical use: compact size, low cost, long lifetime, high robustness and no need for serviceability.
During my ERC Starting Grant project I developed a new route to create high brightness DUVL sources. In this project we will demonstrate the Proof of Concept of a business providing compact, robust, bright and low-cost DUVL sources—based on a down-scaling of my Starting Grant technology—for delivery to confined regions of the body for safe (non-mutagenic to human cells) killing of pathogens.
Status
CLOSEDCall topic
ERC-2019-POCUpdate Date
27-04-2024
Images
No images available.
Geographical location(s)
